Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | SCD | O00767 | 8/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.39 |
| ▸ | IKBKB | O14920 | 1/20 | 0.38 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.38 |
| ▸ | SCN1A | P35498 | 1/20 | 0.38 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.38 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL412178 | 0.85 | KMT2A (0.50) | KMT2ASCD | |
| SCHEMBL12832664 | 0.82 | OPRK1 (0.44) | KMT2AMEN1 | |
| SCHEMBL23456201 | 0.81 | PIK3CD (0.52) | — | |
| SCHEMBL23456200 | 0.81 | PIK3CD (0.52) | — | |
| SCHEMBL1505683 | 0.79 | SSTR4 (0.36) | KMT2AATM | |
| SCHEMBL17112460 | 0.77 | ATXN2 (0.43) | KMT2A | |
| SCHEMBL29663877 | 0.77 | ATXN2 (0.43) | KMT2A | |
| SCHEMBL924247 | 0.74 | KMT2A (0.47) | KMT2AATMALDH1A1 | |
| SCHEMBL3350976 | 0.73 | OPRK1 (0.42) | ATM | |
| SCHEMBL2997545 | 0.73 | LRRK2 (0.40) | KMT2AMEN1SCN1ASCN2ASCN3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011024004-A1 | HETEROCYCLIC UREA DERIVATIVES USEFUL FOR TREATMENT OF BACTERIAL INFECTION | ASTRAZENECA AB (SE) | 2011-03-03 | — | — | WO | disclosed |